

A woman with long, wavy brown hair is shown in profile, looking out over a body of water. She is wearing a dark, textured top. The background is a soft-focus view of a lake or ocean with a distant shoreline. The entire image has a light blue-green tint.

camurus®

Company presentation

March 2024

Forward looking statements

This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance.

Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus' ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases.

Camurus undertakes no obligation to update forward-looking statements.

Camurus snapshot



Rapidly growing commercial stage company

Leader in opioid dependence treatment with Buvidal® weekly and monthly depots



Advancing late-stage pipeline with blockbuster potential

Prospects for multiple new approvals in coming years in CNS and rare disease indications



Strong financial performance

Entered profitability in 2022



Unique FluidCrystal® technology platform

Commercially validated, with a broad range of applications


LISTED ON NASDAQ STOCKHOLM
TICKER **CAMX**; EMPLOYEES: **210+**

Successful 2023 lays foundation for continued profitable growth


-  Strengthened leadership in opioid dependence treatment
-  Brixadi™ launched in the US for treatment of opioid use disorder
-  Positive results and progress in three Phase 3 studies
-  NDA submission for Oclaiz™ (CAM2029) in acromegaly
-  Strong financials and operating performance

Positive financial development

Revenues



Operating results




Outlook 2024

Total revenue
SEK 1740 – 1860 million
+ 33 – 42% excl. one-time
milestones 2023


Profit before tax
SEK 330 – 450 million
+131 – 215% excl. one-time
milestones 2023

camurus®




FluidCrystal[®] extended-release technology

- ✓ Easy and convenient administration
- ✓ Rapid onset & long-acting release
- ✓ Controlled by composition, liquid crystal phase structure and biodegradation
- ✓ Applicable across substance classes
- ✓ Compatible with prefilled syringes, pen-injectors, and other advanced devices
- ✓ Manufacturing by standard processes



Broad and diversified product portfolio and pipeline



¹Licensed to Braeburn in North America; ²Licensed to Rhythm Pharmaceuticals worldwide

Buvidal – game changing opioid dependence treatment

Weekly and monthly, subcutaneous buprenorphine for individualized treatment of opioid dependence within a framework of medical, social and psychological treatment in adults and adolescents 16 years or over¹

Demonstrated benefits to patients and society

- Superior treatment outcome and patient satisfaction²⁻⁵
- Blockade of subjective opioid effects from first dose³
- Reduced treatment burden and improved quality of life^{5,6}
- Decreased risk of diversion, misuse and pediatric exposure^{7,8}
- Reduced treatment costs⁹

**“Buvidal became
my way out”**

Justin, Buvidal patient in
Australia

¹ SmPC Buvidal May 2021; ²Lofwall et al. JAMA Int. Med. 2018;178(6): 764-773; ³Walsh et al, JAMA Psychiatry 2017;74(9):894-902; ⁴Frost, M., et al. Addiction. 2019;114(8):1416-1426. [doi: 10.1111/add.14636](https://doi.org/10.1111/add.14636); ⁵Lintzeris, N., et al. JAMA Network Open. 2021;4(5):e219041. [doi:10.1001/jamanetworkopen.2021.9041](https://doi.org/10.1001/jamanetworkopen.2021.9041); ⁶Barnett et al Drug and Alcohol Dependence 2021; <https://doi.org/10.1016/j.drugalcdep.2021.108959>; ⁷EPAR for Buvidal; ⁸Dunlop, A. J., et al. Addiction. 2021. <https://doi.org/10.1111/add.15627>; ⁹Dunlop, A. Oral presentation at CPDD June 2020.

Buvidal continues to grow in Europe, Australia and MENA


Sales growth across all markets

- Net sales 2023: SEK 1.3 billion; +39% vs 2022
 - Strong performance in key markets in UK, Nordics, Australia
 - Germany, Spain, France growing well from a lower base
- Est. 48,000 patients in treatment with Buvidal end 2023

Market expansion and LCM

- Recent market authorizations in Kuwait and New Zealand (160 mg)
- Four market authorization applications under review
- Several pricing and reimbursement submissions under review
- New launches planned

Quarterly product sales



¹ <https://committees.parliament.uk/publications/41147/documents/203039/default/>

Brixadi™ launch gains momentum in the US

Braeburn responsible for US commercialization

- Focused commercial organization of over 100 people

Wide access to Brixadi for the treatment of OUD

- Available in all 50 US states
- High payer coverage – on par with competition


Accelerated uptake

- SEK 8.3 million royalty vs SEK 1.2 million in Q3
- Est. more than 2,000 US patients in treatment with Brixadi at end-2023¹

Peak market potential est. >USD 1 billion¹

- Brixadi has unique and competitive product profile
- Supportive market dynamics, and increasing awareness of LAI treatment options

US drug overdose deaths per 100,000 residents²




Brixadi™ is the US trade name for Buprenorphine; OUD – opioid use disorder; LAI – long acting injectable

¹Company estimate; ²2018 National Survey on Drug Use and Health; ³Keyes KM, et al. Drug Alc. Dep. Reports 2022; ⁴CDC 2023; ⁵Symphony Health data


Opioid crisis in the US continues

High medical need in the US

~80,000 annual deaths in opioid overdoses¹



Significant treatment gap



¹CDC Provisional Drug Overdose Death Counts; ²2018 National Survey on Drug Use and Health; ³Keyes KM, et al. Drug Alc. Dep. Reports 2022; ⁴CDC 2023; ⁵Symphony Health data

Brixadi – well differentiated in the US market

Convenient and flexible administration

- Weekly and monthly dosing
- Multiple dose strengths (four weekly, three monthly)
- Choice of multiple injection sites
- Thin needle and small dose volumes
- Room temperature stability (no cold chain required)

Strong scientific evidence base

- Superior efficacy and patient reported treatment satisfaction vs daily standard of care

Competitive label¹

- Switch from daily sublingual buprenorphine using conversion table for dose equivalency
- Direct initiation of treatment following a single dose of transmucosal buprenorphine

LAI features²

			
Weekly dosing	–	–	✓
Monthly dosing	✓	✓	✓
Multiple doses	–	–	✓
Choice of inj. sites	–	–	✓
Smallest needle	(19G)	(20G)	✓ (23G)
Lowest dose volume	0.5–1.5mL	3.4mL	✓ 0.16–0.64mL
Room temp. storage	–	–	✓
Day one initiation	–	–	✓
Clin. data vs active control	–	–	✓
Launched	US, CAN, AUS, SE, FI, IL	US	US, EU, UK, AUS

LAI – long acting injectable


¹Brixadi US label; ²See product information

Communicating a growing evidence base

Active scientific conference agenda

	Q4 2023	Q1/Q2 2024		Q3/Q4 2024		
Global		ASAM 4-7 Apr Dallas, US	CPDD 16-19 Jun Montreal, CA	ISAM 5-8 Sep Istanbul, TR		
European	ATHS 24-27 Oct Biarritz, FR	WADD/SEPD 17-20 Apr Mallorca, ES	ALBATROS 5-7 Jun Paris, FR	Lisbon Addict. 23-25 Oct Lisbon, PT		
		EUROPAD 16-19 Jun Lisbon, PT				
National (selected)	APSAD 12-15 Nov Adelaide, AU	SFA 28-29 Mar FR	Federation Add 13-14 Jun Orleans, FR	SOCIDROGA. 26-28 Sep ES	DGS-Kon. Nov Leipzig, DE	Gefängnis-med 5-6 Dec Frankfurt, DE
	DGPPN 4-6 Nov Berlin, DE	RCPsych Addict 27-28 Apr London, UK		Suchtsymp. Oct Grundlsee, AT	CFP Nov France	
	Addiktum Dec Helsinki, Fi	SESP (prisons) 23-25 May ES		Prison Congr. Oct Montpellier, FR	DGPPN Nov Berlin, DE	
	ISPOR Europe 12-15 Nov Copenh, DK	Subst-Forum May Mondsee, AT		APSAD 30 Oct-2 Nov Canberra, AUS	Addiktum Dec Helsinki, FI	

Recent key publications



¹ Walsh S et al, *Neuropsychopharmacology* 2024

² Parkin et al. *Int. J of Drug policy*. 2023

³ Prami T et al, *Nordic studies on drug and alcohol*. 2023

Octreotide SC depot, CAM2029

CAM2029 under development for three
serious rare disease indications

- Acromegaly
- Gastroenteropancreatic neuroendocrine tumors (GEP-NET)
- Polycystic liver disease (PLD)

Designed for enhanced efficacy and
patient convenience

Somatostatin receptor ligands established treatment

Wide use of somatostatin receptor ligands (SRLs)

- Antisecretory, antiproliferative, and immunomodulatory activity
- First-line medical treatment of acromegaly (ACRO) and neuroendocrine tumors (NET)¹
- SRLs also used in other fields of endocrinology and oncology, as well as in gastrointestinal, kidney and liver diseases²

SRL market dominated by long-acting injectables

- Key products: Sandostatin® LAR® (octreotide LAR) and Somatuline® Autogel® (lanreotide ATG)
- Market size approximately US\$ 3 billion³

¹Pavel, M. et al. *Cancer Chemotherapy and Pharmacology*. 2019; 83:375–385. [doi: 10.1007/s00280-018-3734-1](https://doi.org/10.1007/s00280-018-3734-1); ²Gomes-Porras, M. et al. *Int J Mol Sci*. 2020 Mar; 21(5): 1682.
³GlobalData



Key limitations of current SSA therapies

Sandostatin® LAR®



First approved 1998

POSOLGY Monthly intramuscular injection
DOSAGE FORM 19-gauge 38mm needle
DOSE 10-40mg per month, 2.5mL

Limitations:

- Complex reconstitution
- Refrigerated storage
- Large injection needle
- IM injection
- Dosing by trained HCP
- Limited exposure, and efficacy with incomplete symptom control^{1,2}

Somatuline® Autogel®



First approved 2007

POSOLGY Monthly deep subcutaneous injection
DOSAGE FORM 18-gauge 20mm needle
DOSE 60-120mg per month, 0.2-0.5mL

Limitations:

- Refrigerated storage
- Large injection needle
- Deep SC injection
- Dosing by HCP (US)
- Limited efficacy with incomplete symptom control^{1,2}

Mycapssa®



First approved 2020

POSOLGY Twice daily (BID)
DOSAGE FORM Oral capsule
DOSE 40-80mg per day

Limitations^{3,4}:

- Significant food effect requiring dosing under fasting conditions twice daily
- Multiple DDIs
- Modest efficacy – 42% of patients in pivotal trial lost biochemical control (IGF-1) after switch from injectable SSAs
- Not approved in NET

CAM2029 designed to address key limitations

Differentiating features

- ✓ Ready-for-use FluidCrystal[®] technology
- ✓ Rapid onset and long-acting octreotide release¹
- ✓ 5-fold octreotide bioavailability vs Sandostatin LAR with potential for improved efficacy^{1,2,3}
- ✓ State-of-the-art, pre-filled pen injector enabling convenient patient self-administration
- ✓ Subcutaneous administration with thin needle (22-gauge, 12.5mm)
- ✓ Room temperature storage




Source: ¹Tiberg F, et al., *Br J Clin Pharmacol*. 2015; 80(3): 460-472; ²Constant dose; ³Pavel M, et al., *Cancer Chemotherapy and Pharmacology* 2019; 83: 375-383; ⁴Adelman D et al. *Adv Ther*. 2020;37(4):1608-19.




CAM2029 provides high SRL exposure

~5x higher octreotide plasma exposure for CAM2029 vs. Sandostatin LAR

CAM2029 octreotide plasma levels in the range of immediate release octreotide



Status overview of CAM2029 programs by indication



Timelines are indicative. PK – pharmacokinetic; PD – pharmacodynamic; RCT – randomized control trial; LST – long-term safety trial; ACRO – acromegaly, GEP-NET – gastroenteropancreatic neuroendocrine tumors; PLD – polycystic liver disease


NDA submission in acromegaly following positive ACROINNOVA Phase 3 study results

Key milestones achieved for CAM2029


- ✓ Positive ACROINNOVA 1 Phase 3 results¹
 - Demonstrating superior biochemical control vs placebo
 - Improved convenience and quality of life vs SoC
 - Safety profile consistent with 1st generation SRLs
- ✓ Positive ACROINNOVA 2 interim Phase 3 results²
 - Reinforcing long-term safety and effectiveness
 - Improved symptom control, treatment satisfaction and quality of life scores vs SoC at baseline
- ✓ Population PK and PKPD models developed
- ✓ Positive pre-NDA meetings
- ✓ NDA submission of Oclaiz™ in acromegaly³
 - Submission date 21 December 2023

Efficacy demonstrated in ACROINNOVA 1 & 2^{1,2}

IGF-1 values over time (mean, 95% CI)



Proportion of responders over time (IGF-1 ≤ ULN)



SoC – standard-of-care; SRL – somatostatin receptor ligand

¹Press release 20 June 2023; ²Press release 17 July 2023; ³Press release 21 December 2023;

CAM2029 has an attractive product profile in acromegaly



Once-monthly self-administration with prefilled pen



Improved convenience and treatment satisfaction^{1,2}



Long-acting release with ~5X octreotide bioavailability^{3,4}




High rates of biochemical control¹



Improved symptom control & quality of life²

Improved symptom scores*



* The Acromegaly Index of Severity (AIS) score was calculated as the sum of the scores for the six symptoms of headache, sweating, fatigue, joint pain, paresthesia and soft tissue swelling. The AIS score ranges from 0 (no symptoms) to 18 (severe symptoms)

ACROINNOVA 1

Phase 3 RCT efficacy and safety trial

ACROINNOVA 1 trial design

- 24-week, randomized, double blind, placebo-controlled trial

Key eligibility criteria:

- Patients with acromegaly on treatment with a stable dose of octreotide LAR or lanreotide ATG for at least 3 months with
- IGF-1 levels $\leq 1 \times \text{ULN}$ at screening

Primary endpoint:


- Proportion of patients with mean IGF-1 $\leq 1 \times \text{ULN}$ (week 22 and 24)

Key secondary endpoints:

- Proportion of patients with mean IGF-1 levels $\leq 1 \times \text{ULN}$, incl. patients with decreased dose
- Proportion of patients with mean IGF-1 levels $\leq 1 \times \text{ULN}$ and GH cycle levels $< 2.5 \mu\text{g/L}$


Secondary endpoints, e.g.:

- Time to loss of IGF-1 response
- IGF-1 and GH over time and change from baseline
- Clinical signs and symptoms (AIS score)
- Patient satisfaction and treatment satisfaction (PSS and TSQM)
- Acromegaly quality of life (AcroQoL)
- Self-injection assessments (SiAQ)
- Plasma concentrations of octreotide
- Safety and tolerability



Completed patient recruitment in Phase 3 SORENTO study of CAM2029 in GEP-NET

Enrollment across 12 countries exceeding randomization target (302)



SORENTO assessing CAM2029 superiority in PFS

Randomized, active-controlled Phase 3 trial

- Randomized, multi-center, open-label, active-controlled Phase 3 trial of CAM2029 vs. long-acting octreotide or lanreotide in patients with GEP-NET
- Single trial fulfilling regulatory requirements for safety and efficacy

Patient population


- Patients with confirmed, advanced and well-differentiated GEP-NET (grade 1 to grade 3)

Primary endpoint

- Superiority in progression free survival, PFS, vs. standard of care (first-line medical treatment)
- Assessed after 194 documented PFS events

Secondary endpoints include

- Overall survival
- PROs (e.g., treatment satisfaction, quality of life)
- Plasma concentrations of octreotide
- Safety




Clinical Phase 2/3 study in PLD fully recruited

POSITANO trial to assess efficacy and safety


- 53-week randomized, placebo-controlled, three-arm trial
 - Randomization of 71 patients completed in February 2024
 - Primary endpoint is liver volume change
 - Key secondary endpoint is Camurus' developed PRO, PLD-S
 - Multiple secondary endpoints, incl. quality of life, safety, etc.
- Open label extension extended to 120 weeks
 - Offer continued treatment in patients with expected benefits

Large unmet medical need in PLD

- Severe quality-of-life implications for patients with symptomatic PLD
- No labelled option available



positano™



CAM2029 progressing towards market with key upcoming key milestones 2024/25

AcroInnova™

Pivotal randomized placebo controlled and long-term safety trials in acromegaly

- ✓ Positive ACROINNOVA 1 results
- ✓ Positive ACROINNOVA 2 interim results
- ✓ NDA submission
- ❑ **NDA acceptance for review expected Q1 2024**
- ❑ **MAA submission H1 2024**
- ❑ **NDA approval decision expected Q4 2024**
- ❑ **US launch Q1 2025**

SORENTO™

Subcutaneous Octreotide Randomized Efficacy in Neuroendocrine Tumors

- ✓ SORENTO Phase 3 start Q4 2021
- ✓ SORENTO fully enrolled Q4 2023
- ❑ **Topline result H1 2025**
- ❑ **NDA/MAA submission H2 2025**

positano™

Polycystic liver Safety and efficacy Trial with subcutaneous Octreotide

- ✓ POSITANO Phase 2/3 Q2 2022
- ✓ POSITANO fully enrolled Q1 2024
- ❑ **Topline result H1 2025**

High market potential for CAM2029 – largest opportunity in GEP-NET

Attractive specialty pharma opportunity

- Blockbuster potential in NET
- Highly concentrated target audiences
- Differentiated product features
- Switch from established first-line treatments

CAM2029 peak sales estimates from third party market research¹⁻⁴

	TERRITORY	PATIENT POPULATION	EST. PEAK PATIENT SHARE	EST. PEAK SALES
ACRO	EU/AUS US	16,500 ⁴ 10,000	20 – 35% 25 – 40%	€30 – 65 million \$150 – 280 million
NET ¹	EU/AUS US	68,000 ⁴ 37,000	30% 40%	€300 – 400 million \$1,200 – 1,500 million
PLD ¹	EU/AUS US	15-18,000 ⁴ 12-13,000	30 – 40% 30 – 40%	€80 – 100 million \$200 – 300 million

¹Globe Life Science Aug 2022, data on file; ²Globe Life Science 2020, data on file; ³Assuming €10-12.5ks (EU/AUS) and \$60-70K (US) per year net pricing in acromegaly, €15-20k (EU/AUS) and \$80-100K (US) per year net pricing in NET, and €17.5k (EU/AUS) and \$60K (US) per year net pricing in PLD; ⁴Patient numbers extrapolated from 5EU estimates by assuming same prevalence across European countries and Australia



Building commercial infrastructure in the US

US launch preparations Oclaiz™ in acromegaly


Key activities

- Camurus Inc. fully operational
- President Camurus US appointed
- In-depth market research
- Medical affairs activities
- Payor engagement
- Distribution model

Key scientific conferences for CAM2029 in 2024

	Q1 2024	Q2 2024	Q3 2024	Q4 2024	
Global	ICE 1-4 March Dubai UAE	AACE2023 9-11 May New Orleans US	ENDO 1-4 Jun Boston US	ENEA 11-13 Sep Sevilla ES	NANETS 12-14 Oct Chicago US
					AASLD Nov 15-19 San Diego, US
European	ENETS 22-24 Mar Vienna AT	ECE 11-14 May Stockholm SE	EASL 5-8 Jun Milan IT		
		ACRO	NET	PLD	

Regulatory timeline:



Strong foundation for continued value creation

-  Buvidal growth in Europe and Australia
-  Positive launch momentum for Brixadi in the US
-  Pipeline progress towards new approvals and launches
-  Establishing a US commercial organization
-  Strong financial position to support sustainable growth



Camurus AB | Ideon Science Park, SE-223 70 Lund, Sweden
P +46 46 286 57 30 | info@camurus.com | camurus.com

Progress towards Camurus' Vision 2027

Status update end-2023 following one year of execution towards the five-year vision

5x

Five-fold revenue growth
(from 2022)



**Establishment
of US commercial infrastructure**

4

Approvals for four R&D
pipeline programs

~50%

Operating margin around 50%

5x revenue growth in 5 years

SEK 1.7bn 2023

☐ SEK 4.5 billion in 2027

Buvidal patients grew 33%

48,000 in 2023

☐ >100,000 patients in 2027

Brixadi, opioid use disorder

- ✓ US launch in September 2023
- ☐ >\$1 billion peak sales potential

US commercial infrastructure

Preparing for Oclaiz™ launch

- ✓ Camurus Inc. fully operational
- ✓ Behshad Sheldon appointed President Camurus US
- ☐ Launch-ready Q4 2024

Accelerated commercial build-up

- ✓ Strengthened financial position
- ☐ Accelerate commercial readiness in NET and PLD

New approvals

1 of 4

Brixadi, opioid use disorder

- ✓ US approved in May 2023

Oclaiz™ (CAM2029) in acromegaly

- ✓ NDA submitted in December 2023
- ☐ US approval decision exp. Q4 2024

CAM2029 GEP-NET

- ✓ Completed Phase 3 recruitment in Q4 2023
- ☐ NDA submission est. 2025

Operating margin

31% in 2023

☐ ~50% in 2027

Operational excellence

- ✓ Increased gross margin
- ☐ Disciplined capital allocation to invest in the pipeline and commercialization

Supported by inorganic growth

- ✓ Proceeds of SEK 1.1 billion directed share issue in January 2024
- ☐ Grow and diversify revenues through partnerships and acquisition

Key milestones coming 12 months

R&D Pipeline

- ✓ Completed recruitment in POSITANO study in PLD
- ❑ FDA acceptance for review of Oclaiz™ NDA
- ❑ MAA submission of CAM2029 in acromegaly to EMA
- ❑ FDA approval of Oclaiz™ in acromegaly
- ❑ Topline results SORENTA study in GEP-NET
- ❑ Topline results POSITANO study in PLD
- ❑ Start new clinical program

Commercial and corporate development

- ✓ Directed share issue raising gross proceeds of SEK 1.1 billion
- ❑ US commercial organization fully established
- ❑ Business development and inorganic growth
- ❑ US launch of Oclaiz™ in acromegaly



Shareholders and analyst coverage

Shareholders as of 31 January 2024	Number of shares	% of capital	% of votes
Sandberg Development AB	21,875,692	38.0	38.0
Fjärde AP-fonden	2,487,654	4.3	4.3
Avanza Pension	1,714,091	3.0	3.0
Swedbank Robur Fonder	1,670,277	2.9	2.9
Fredrik Tiberg, CEO	1,615,000	2.8	2.8
State Street Bank and Trust	1,315,120	2.3	2.3
The Bank of New York Mellon SA/NV	1,267,899	2.2	2.2
Handelsbankens fonder	1,255,927	2.2	2.2
JP Morgan Chase Bank	1,229,513	2.1	2.1
Afa Försäkring	716,293	1.2	1.2
CS Client Omnibus ACC	555,156	1.0	1.0
The Bank of New York Mellon	532,334	0.9	0.9
SEB Investment Management	530,097	0.9	0.9
JP Morgan SE, Luxemburg branch	515,932	0.8	0.8
SEB AB, Luxemburg branch	488,224	0.8	0.8
Other shareholders	19,842,909	34.4	34.4
In total	57,612,118	100.0	100.0

Analysts

Carnegie

Erik Hultgård

DNB

Patrik Ling

Handelsbanken

Suzanna Queckbörner

Mattias Häggblom

Jefferies

James Vane-Tempest

Nordea

Viktor Sundberg

Pareto

Dan Akschuti

Bryan Garnier

Alex Cogut

Experienced and committed management team



Fredrik Tiberg, PhD
President & CEO, CSO
In Company since 2002
Holdings: 1,600,000 shares,
15,000 subscription warrants
& 102,000 employee options

Education: M.Sc. in Chem. Eng., Lund Institute of Technology, PhD and Assoc. Prof. Physical Chemistry, Lund University.
Previous experience: More than 20 years executive leadership experience from the pharmaceutical industry. Professor Physical Chemistry, Lund University; Visiting Professor at Oxford University; Section Head, Institute for Surface Chemistry.



Jon Garay Alonso
Chief Financial Officer
In Company since: 2022
Holdings: 1,450 shares &
57,750 employee options

Education: Bachelor in Business Administration by Universidad Comercial de Deusto. Executive MBA by IESE Business School.
Previous experience: More than 20 years experience from Finance within pharmaceutical and medtech companies, incl. Baxter, Gambro, Convatec, Bristol Myers Squibb.



Maria Lundqvist
Head of Global HR
In Company since 2021
Holdings: 38,500 employee
options

Education: B.Sc. in Business and Economics, Uppsala University
Previous experience: More than 20 years of experience of leadership roles within Human Resources, including HR Director Nordics at Teva Pharmaceuticals and HR positions at Tetra Pak, Vestas and AstraZeneca.



Richard Jameson
Chief Commercial Officer
In Company since: 2016
Holdings: 29,193 shares, 8,000
subscription warrants and
57,750 employee options

Education: B.Sc. in Applied Biological Sciences from University West of England
Previous experience: General Manager, UK & Nordics for Reckitt Benckiser (2010 – 2013) and Area Director Europe, Middle East and Africa for Indivior (2013 – 2016).



Fredrik Joabsson, PhD
Chief Business Dev. Officer
In Company since 2001
Holdings: 50,170 shares &
38,500 employee options

Education: M.Sc. in Chemistry, PhD in Physical Chemistry, Lund University
Previous experience: More than 20 years of experience in pharmaceutical R&D, business development and alliance management.



Markus Johnsson
Senior VP R&D
In Company since: 2003-2017,
2019-
Holdings: 21,000 shares &
23,500 employee options

Education: Ph.D. in physical chemistry and M.Sc. in chemistry from Uppsala University.
Previous experience: More than 20 years of experience from pharmaceutical development and project management



Torsten Malmström, PhD
Chief Technical Officer
In Company since 2013
Holdings: 46,858 shares &
38,500 employee options

Education: M.Sc. in Chemistry, PhD in Inorganic Chemistry, Lund University
Previous experience: More than 20 years of experience from pharmaceutical R&D including Director Pharmaceutical Development at Zealand Pharma, Director of Development at Polypeptide, Team Manager at AstraZeneca.



Annette Mattsson
VP Regulatory Affairs
In Company since: 2017
Holdings: 2,004 shares, 1,000
subscription warrants &
38,500 employee options

Education: Bachelor of Pharmacy, Uppsala University and Business Economics, Lund University
Previous experience: More than 25 years of experience within regulatory affairs, including European RA Director/Global RA Lead at AstraZeneca and Global RA Lead at LEO Pharma.



Alberto M. Pedroncelli
Chief Medical Officer
In Company since 2023
Holdings: 1,000 shares &
20,000 employee options

Education: MD University of Milan. Ph. D. endocrinology post-graduate school University of London
Previous experience: Head of Clinical Development and Medical Affairs Recordati, Senior Leadership positions Novartis, clinician and research fellow Dept. Endocrinology, University Hospital Bergamo, Italy



Agneta Svedberg
VP Clinical & Regulatory Dev.
In Company since: 2015
Holdings: 22,987 shares &
38,500 employee options

Education: M.Sc. In Radiophysics and B.Sc. In Medicine from Lund University, Executive MBA from Executive Foundation Lund
Previous experience: More than 25 years of experience in drug development, incl. as COO at Zealand Pharma, CEO of Cantargia, Senior VP Clinical Development at Genmab.